Clinical Trials on Hemobilia in Denmark

Total 38 results

University of Aarhus

Completed

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

Hemophilia A

Denmark
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Haemophilia A

Denmark
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
Swedish Orphan Biovitrum

Completed

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B (MIND)

Haemophilia A | Haemophilia B

Sweden, Finland, Denmark
Bayer

Completed

International PMS Study - KOGENATE Bayer

Hemophilia A

Switzerland, France, Spain, Sweden, Austria, Italy, Belgium, Denmark, Greece, Netherlands
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Novo Nordisk A/S

Completed

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Denmark, France, United Kingdom
Bayer

Completed

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Hemophilia A

Bulgaria, Spain, Italy, Poland, Greece, Norway, Denmark
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
CSL Behring

Active, not recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Hemophilia B

United States, Belgium, Netherlands, Denmark, Germany, Ireland, Sweden, United Kingdom
PedNet Haemophilia Research Foundation
Lund University Hospital

Recruiting

The European Paediatric Network for Haemophilia Management ( PedNet Registry) (PedNet)

Factor IX Deficiency | Factor VIII Deficiency

Norway, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Hemophilia A | Hemophilia B

United States, Australia, China, Denmark, France, Israel, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, South Africa, Spain, Taiwan, Hungary, Italy
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (ATLAS-PPX)

Hemophilia

United States, Australia, China, Denmark, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Mexico
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
Novo Nordisk A/S

Completed

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors (explorer™4)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Austria, Spain, Japan, Croatia, Italy, United Kingdom, Israel, Sweden, Ukraine, Malaysia, Greece, Denmark, Canada
Pfizer

Recruiting

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B (BASIS KIDS)

Hemophilia A | Hemophilia B

Denmark, Taiwan, Canada, Turkey, Spain, China, United Kingdom, South Africa, Saudi Arabia, Israel, Korea, Republic of, Austria, Germany, Japan, Australia, Italy, India, Slovakia, France, United States, Brazil, Argentina
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8)

Haemophilia A Without Inhibitors | Haemophilia B Without Inhibitors

Spain, United States, Korea, Republic of, United Kingdom, Australia, Lithuania, France, Turkey, India, Estonia, Russian Federation, Ukraine, Mexico, Japan, South Africa, Serbia, Canada, Croatia, Algeria, Bosnia and Herzegovina, ... and more
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (explorer7)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Spain, Korea, Republic of, India, Australia, United Kingdom, Russian Federation, Poland, Ukraine, Thailand, Mexico, United States, Turkey, Japan, South Africa, Serbia, France, Croatia, Denmark, Algeria, Bulgaria, Malaysia, Portugal, Slovaki... and more
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Pfizer

Terminated

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Hemophilia A

Netherlands, Spain, Greece, Italy, France, Belgium, Germany, Austria, Sweden, Hungary, Finland, United Kingdom, Denmark, Romania
Genzyme, a Sanofi Company

Active, not recruiting

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)

Hemophilia

China, Hungary, Turkey, Canada, Korea, Republic of, United States, Australia, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Malaysia, South Africa, Taiwan, Ukraine, United Kingdom
Bayer

Completed

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)

Hemophilia A

Korea, Republic of, Taiwan, Turkey, Singapore, United States, Netherlands, Austria, Denmark, United Kingdom, Belgium, Italy, France, Japan, Germany, Israel, Poland, Canada, Norway, Romania, Colombia
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Hemophilia A

Spain, United States, Denmark, Italy, Taiwan, Malaysia, Belgium, Thailand, Turkey, Austria, Bulgaria, Canada, Finland, France, Germany, Hong Kong, Hungary, Korea, Republic of, Netherlands, Norway, Singapore, Ukraine, United Kingdom
Bayer

Completed

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (Leopold I)

Hemophilia A | Blood Coagulation Disorders

Spain, Taiwan, Austria, United States, Germany, Thailand, United Kingdom, Italy, Turkey, Croatia, Serbia, Poland, Israel, Sweden, Indonesia, Argentina, Norway, South Africa, India, Hong Kong, Denmark, Pakistan
Bayer

Terminated

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, Canada, Switzerland, Estonia, Taiwan, France, Chile, Netherlands, United Kingdom, Austria, New Zealand, South Africa, Romania, Croatia, Israel, Germany, Poland, Australia, Denmark, Turkey, Argentina, Lithuan... and more
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Novo Nordisk A/S

Recruiting

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) (FRONTIER4)

Haemophilia A With Inhibitors | Haemophilia A

Taiwan, Canada, Spain, Netherlands, Korea, Republic of, India, United States, United Kingdom, China, Portugal, Lithuania, Turkey, South Africa, Ireland, Italy, France, Japan, Belgium, Germany, Malaysia, Poland, Austria, Bulgaria, Denmark and more
Novo Nordisk A/S

Recruiting

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

Haemophilia A With Inhibitors | Haemophilia A

United States, Korea, Republic of, France, Spain, Romania, Canada, Taiwan, China, Lithuania, Netherlands, India, South Africa, Russian Federation, Austria, Belgium, Czechia, Denmark, Germany, Ireland, Italy, Japan, Latvia, Malaysia, M... and more
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (guardian™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Germany, Switzerland, Serbia, Taiwan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Japan, Denmark, Hungary, Israel, Turkey, Russian Federation, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...

Clinical Trials on Hemobilia in Denmark

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations